San Francisco, Ca., USA - April 16, 2009, San Francisco, Ca., USA - Proteolix, Inc. announced the appointment of Craig C. Parker to the post of Senior Vice President, Finance and Corporate Development and CFO.
Article continues below
In addition to that, company appointed Michael G. Kauffman, M.D., Ph.D., to the post of Chief Medical Officer (CMO) and Albert L. Kraus, Ph.D., to the newly-created position of Vice President, Regulatory Affairs and Quality Assurance.
Mr. Parker received his undergraduate degree in Biological Sciences from the University of Chicago, an MBA from the University of Michigan Stephen M. Ross School of Business, and attended the Georgetown University School of Medicine. Mr. Parker brings more than 15 years of finance and business development leadership in the biotechnology industry to Proteolix. Mr. Parker’s career includes 12 years as a Wall Street research analyst. From 2002 - 2007, he was a Managing Director and head of Biotechnology Equity Research at Lehman Brothers. He also covered the biotechnology industry as the senior biotechnology analyst at Donaldson, Lufkin & Jenrette from 1998 - 1999, and as an analyst at JP Morgan from 1994-1998. Mr. Parker’s operating experience includes serving as Senior Vice President and General Manager of the Specialty Therapeutics Franchise at Immunex Corporation from 1999 - 2001.
Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins and holds a B.A. in biochemistry from Amherst College. He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital. Dr. Kauffman, previously a member of Proteolix’s Board of Directors, was a clinical developer at Millennium Pharmaceuticals (now a subsidiary of Takeda Pharmaceutical Company). Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc. Dr. Kauffman also served as Medical Director at Biogen Corporation (now Biogen Idec). ■